Corcept officer plans $22M sale of 175K shares

CORCEPT THERAPEUTICS INC (CORT) received a Rule 144 notice for a proposed sale of up to 175,000 shares of common stock for the account of officer Sean Maduck, with Stifel Nicolaus & Company Inc listed as broker.

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) received a Rule 144 notice for a proposed sale of up to 175,000 shares of common stock for the account of officer Sean Maduck, with Stifel Nicolaus & Company Inc listed as broker. The shares derive from stock option awards dated February 8, 2019 (100,000 shares) and February 10, 2017 (75,000 shares), categorized as equity compensation. Over the prior three months, Maduck reported sales totaling multiple tranches of common stock, including 75,000 shares on May 27, 2026 and several smaller sales through August 14, 2026.

Key Figures

Shares proposed for sale: 175,000 shares of common stock Aggregate value of shares: $21,976,448.00 2019 stock option award shares: 100,000 shares +5 more

8 metrics

Shares proposed for sale 175,000 shares of common stock Maximum number of CORCEPT THERAPEUTICS INC shares covered by this Rule 144 notice

Aggregate value of shares $21,976,448.00 Value associated with the 175,000 shares of common stock proposed for sale

2019 stock option award shares 100,000 shares Common stock underlying stock option award dated February 8, 2019 categorized as equity compensation

2017 stock option award shares 75,000 shares Common stock underlying stock option award dated February 10, 2017 categorized as equity compensation

Shares sold on May 27, 2026 75,000 shares Common stock sale by Sean Maduck with aggregate amount $4,918,950.00

Amount from May 27, 2026 sale $4,918,950.00 Aggregate dollar amount for 75,000 common shares sold on May 27, 2026

Shares sold on June 1, 2026 25,000 shares Common stock sale by Sean Maduck with aggregate amount $1,755,182.00

Shares sold on July 1, 2026 25,000 shares Common stock sale by Sean Maduck with aggregate amount $2,208,736.00

Key Terms

Rule 144, Stock Option Award, Equity Compensation, attorney-in-fact

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Award financial

"Common Stock | 02/08/2019 | Stock Option Award | Issuer"

A stock option award is a grant that gives an employee the right to buy a company’s shares at a fixed price for a limited time, often becoming available gradually over a set schedule. Investors care because these awards align workers’ incentives with company performance, can increase employee loyalty, and may create future share dilution and compensation expense that affect earnings per share and shareholder value.

Equity Compensation financial

"100000 | 08/25/2026 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

attorney-in-fact regulatory

"as a duly authorized representative of STIFEL, as attorney-in-fact for Sean"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for CORCEPT THERAPEUTICS INC (CORT)?

It discloses a proposed sale under Rule 144 of up to 175,000 shares of CORCEPT THERAPEUTICS INC common stock for the account of officer Sean Maduck, with Stifel Nicolaus & Company Inc as broker, from stock option awards granted in 2017 and 2019.

Who is selling shares of CORT under this Form 144 and in what capacity?

The proposed sale is for the account of Sean Maduck, identified as an officer of CORCEPT THERAPEUTICS INC. The notice is signed by James Weimer as a duly authorized representative of Stifel, acting as attorney-in-fact for Maduck.

How many CORT shares are proposed to be sold and from which awards?

The notice covers a proposed sale of up to 175,000 common shares, consisting of 100,000 shares from a February 8, 2019 stock option award and 75,000 shares from a February 10, 2017 stock option award, each categorized as equity compensation.

What recent CORT share sales by Sean Maduck are reported in the last 3 months?

Reported past 3‑month sales include 75,000 shares on May 27, 2026, 25,000 on June 1, 2026, 25,000 on July 1, 2026, and additional smaller sales of 20,305, 1,031, and 3,664 shares on dates through August 14, 2026.

What aggregate value is associated with the proposed CORT shares in this Form 144?

The filing lists an aggregate value of $21,976,448.00 for the 175,000 CORCEPT THERAPEUTICS INC common shares covered by the notice, as shown in the securities information section.

Which broker is handling the proposed Rule 144 sale for CORT shares?

The broker listed is Stifel Nicolaus & Company Inc, located at 501 N Broadway, St. Louis, Missouri, which is identified in connection with the 175,000 CORCEPT THERAPEUTICS INC common shares proposed to be sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 05:25 PM EDT Accepted by SEC EDGAR 08/25/2026 - 05:24 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001698310
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CORCEPT THERAPEUTICS INC
SEC File Number	000-50679
Address of Issuer	101 REDWOOD SHORES PARKWAY REDWOOD CITY CALIFORNIA 94065
Phone	650.688.8803
Name of Person for Whose Account the Securities are To Be Sold	Maduck Sean
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	175000	21976448.00	108098397	08/25/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/08/2019	Stock Option Award	Issuer			100000	08/25/2026	Equity Compensation
Common Stock	02/10/2017	Stock Option Award	Issuer			75000	08/25/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sean Maduck 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065	Common Stock	05/27/2026	75000	4918950.00
Sean Maduck 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065	Common Stock	06/01/2026	25000	1755182.00
Sean Maduck 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065	Common Stock	07/01/2026	25000	2208736.00
Sean Maduck 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065	Common Stock	08/03/2026	20305	2329075.00
Sean Maduck 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065	Common Stock	08/10/2026	1031	118068.00
Sean Maduck 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065	Common Stock	08/14/2026	3664	419491.00

144: Remarks and Signature

Remarks
Date of Notice	08/25/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/08/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ James Weimer, as a duly authorized representative of STIFEL, as attorney-in-fact for Sean Maduck
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)